AAN 2026 18 - 22 April 2026

Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial

Authors :

Dylan Belmont-Rausch1, MartíJiménezMausbach1, JanChristianRefsgaard1,GabrielMartino1,TeresaLeonColombo1,BettyTijms2,ClarePaterson3

 

Affiliations
View Details Hide Details
Download .PDF
Keywords
Neurodegenerative diseases
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)